MORPHIC HOLDING INC (MORF) Stock Price & Overview
NASDAQ:MORF • US61775R1059
Current stock price
The current stock price of MORF is 56.99 USD. Today MORF is up by 0.04%. In the past month the price increased by 1.19%. In the past year, price increased by 5.11%.
MORF Key Statistics
- Market Cap
- 2.855B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.75
- Dividend Yield
- N/A
MORF Stock Performance
MORF Stock Chart
MORF Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MORF. When comparing the yearly performance of all stocks, MORF is one of the better performing stocks in the market, outperforming 94.75% of all stocks.
MORF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MORF. No worries on liquidiy or solvency for MORF as it has an excellent financial health rating, but there are worries on the profitability.
MORF Earnings
MORF Forecast & Estimates
15 analysts have analysed MORF and the average price target is 59.6 USD. This implies a price increase of 4.57% is expected in the next year compared to the current price of 56.99.
For the next year, analysts expect an EPS growth of -16.05% and a revenue growth -50.42% for MORF
MORF Groups
Sector & Classification
MORF Financial Highlights
Over the last trailing twelve months MORF reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS decreased by -15.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.83% | ||
| ROE | -29.08% | ||
| Debt/Equity | 0 |
MORF Ownership
MORF Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MORF
Company Profile
Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Company Info
IPO: 2019-06-27
MORPHIC HOLDING INC
35 Gatehouse Drive A2
Waltham MASSACHUSETTS 02451 US
CEO: Praveen P. Tipirneni
Employees: 124
Phone: 17819960955
MORPHIC HOLDING INC / MORF FAQ
Can you describe the business of MORPHIC HOLDING INC?
Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
What is the current price of MORF stock?
The current stock price of MORF is 56.99 USD. The price increased by 0.04% in the last trading session.
Does MORPHIC HOLDING INC pay dividends?
MORF does not pay a dividend.
How is the ChartMill rating for MORPHIC HOLDING INC?
MORF has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy MORF stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MORF.
What is the market capitalization of MORF stock?
MORPHIC HOLDING INC (MORF) has a market capitalization of 2.85B USD. This makes MORF a Mid Cap stock.